- Revenue decline due to significant provisions for impairment loss on receivables, reversal of deferred tax assets, and strategic transition from vaccines to immunotherapy and cell therapies.
- Decline in cash and bank balances due to robust business development activities.
- Increased total liabilities due to higher lease liabilities.
Malaysian Genomics Resource Centre Berhad
Greenhouse gas emissions & sustainability report data
In its 2023 reporting, Malaysian Genomics Resource Centre Berhad disclosed greenhouse gas emissions of Scope 2: 371.66 tonnes; Scope 3 (employee commute only): 135.04 tonnes; Scope 1: Null. By scope: Scope 2: 371.66 tCO2e/year; Scope 3: 135.04 tCO2e/year. Figures are as stated in the company's own report and may use different boundaries, units or methods (for example market-based vs location-based Scope 2), so compare with care.
GHG Emissions
Scope 2: 371.66 tonnes; Scope 3 (employee commute only): 135.04 tonnes; Scope 1: Null
2023
Water Usage
1.6K m3/year
2023
Waste
2.21 tons/year (clinical waste)
2023
Energy Use
635.5K kWh/year
2023
📊 Emissions by Scope (2023)
| Scope | What it covers | Reported value |
|---|---|---|
| Scope 2 | Indirect emissions from purchased electricity, steam, heat and cooling. | 371.66 tCO2e/year |
| Scope 3 | Other indirect emissions across the value chain (purchased goods, business travel, use of sold products, etc.). | 135.04 tCO2e/year |
New to scopes? Read Scope 1, 2 and 3 emissions explained and market-based vs location-based Scope 2.
✅ Reported Environmental Achievements
- Reduced energy consumption through various initiatives (Specific figures in kWh provided in the report, but not a percentage reduction).
🎯 Climate & Sustainability Targets
🔭 Long-term
- To evolve into a leading specialist healthcare group.
🌱 ESG Focus Areas
People DevelopmentCustomer SatisfactionStakeholder PartnershipsPreventive and Precision Healthcare